These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 16614389)
41. Differential regulation of membrane associated-growth hormone binding protein (MA-GHBP) and growth hormone receptor (GHR) expression by growth hormone (GH) in mouse liver. González L; Curto LM; Miquet JG; Bartke A; Turyn D; Sotelo AI Growth Horm IGF Res; 2007 Apr; 17(2):104-12. PubMed ID: 17321774 [TBL] [Abstract][Full Text] [Related]
42. CIDE-A gene expression is decreased in white adipose tissue of growth hormone receptor/binding protein gene disrupted mice and with high-fat feeding of normal mice. Kelder B; Berryman DE; Clark R; Li A; List EO; Kopchick JJ Growth Horm IGF Res; 2007 Aug; 17(4):346-51. PubMed ID: 17544797 [TBL] [Abstract][Full Text] [Related]
43. Regulation of growth hormone receptors in human prostate cancer cell lines. Bidosee M; Karry R; Weiss-Messer E; Barkey RJ Mol Cell Endocrinol; 2009 Oct; 309(1-2):82-92. PubMed ID: 19540305 [TBL] [Abstract][Full Text] [Related]
44. Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. Vera M; Sobrevals L; Zaratiegui M; Martinez L; Palencia B; Rodríguez CM; Prieto J; Fortes P Gene Ther; 2007 Feb; 14(3):203-10. PubMed ID: 17024107 [TBL] [Abstract][Full Text] [Related]
45. Ethinylestradiol differentially interferes with IGF-I in liver and extrahepatic sites during development of male and female bony fish. Shved N; Berishvili G; D'Cotta H; Baroiller JF; Segner H; Eppler E; Reinecke M J Endocrinol; 2007 Dec; 195(3):513-23. PubMed ID: 18000313 [TBL] [Abstract][Full Text] [Related]
46. Effects of chronic cysteamine treatment on growth enhancement and insulin-like growth factor I and II mRNA levels in common carp tissues. Tse MC; Cheng CH; Chan KM Br J Nutr; 2006 Oct; 96(4):650-9. PubMed ID: 17010223 [TBL] [Abstract][Full Text] [Related]
47. Regulation of endocrine and paracrine sources of Igfs and Gh receptor during compensatory growth in hybrid striped bass (Morone chrysops X Morone saxatilis). Picha ME; Turano MJ; Tipsmark CK; Borski RJ J Endocrinol; 2008 Oct; 199(1):81-94. PubMed ID: 18628362 [TBL] [Abstract][Full Text] [Related]
48. Survival and cellular immune functions in septic mice treated with growth hormone (GH) and insulin-like growth factor-I (IGF-I). Schmitz D; Kobbe P; Lendemanns S; Wilsenack K; Exton M; Schedlowski M; Oberbeck R Growth Horm IGF Res; 2008 Jun; 18(3):245-52. PubMed ID: 18023601 [TBL] [Abstract][Full Text] [Related]
50. Metabolic adaptations associated with irreversible glucose loss are different to those observed during under-nutrition. Meier S; Gore PJ; Barnett CM; Cursons RT; Phipps DE; Watkins KA; Verkerk GA Domest Anim Endocrinol; 2008 Apr; 34(3):269-77. PubMed ID: 17897805 [TBL] [Abstract][Full Text] [Related]
51. Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice. Lamb CA; Helguero LA; Giulianelli S; Soldati R; Vanzulli SI; Molinolo A; Lanari C Breast Cancer Res; 2005; 7(6):R1111-21. PubMed ID: 16457691 [TBL] [Abstract][Full Text] [Related]
52. Normalization of growth in hypophysectomized mice using hydrodynamic transfer of the human growth hormone gene. Sondergaard M; Dagnaes-Hansen F; Flyvbjerg A; Jensen TG Am J Physiol Endocrinol Metab; 2003 Aug; 285(2):E427-32. PubMed ID: 12657568 [TBL] [Abstract][Full Text] [Related]
53. Opposite regulation of IGF-I and IGF-I receptor mRNA and concomitant changes of GH receptor and IGF-II/M6P receptor mRNA in human IM-9 lymphoblasts. Yang Y; Hoeflich A; Butenandt O; Kiess W Biochim Biophys Acta; 1996 Feb; 1310(3):317-24. PubMed ID: 8599610 [TBL] [Abstract][Full Text] [Related]
54. Antisense oligonucleotides: efficient synthesis of 2'-O-methoxyethyl phosphorothioate oligonucleotides using 4,5-dicyanoimidazole. Are these oligonucleotides comparable to those synthesized using 1H-tetrazole as coupling activator? Wang Z; Siwkowski A; Lima WF; Olsen P; Ravikumar VT Bioorg Med Chem; 2006 Jul; 14(14):5049-60. PubMed ID: 16563772 [TBL] [Abstract][Full Text] [Related]
55. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045 [TBL] [Abstract][Full Text] [Related]
56. Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides. Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D; Tsutsumi S; Kawai K Oligonucleotides; 2006; 16(3):253-62. PubMed ID: 16978088 [TBL] [Abstract][Full Text] [Related]
58. Growth hormone-dependent changes in the rat lung proteome during alveorization. Beyea JA; Olson DM; Harvey S Mol Cell Biochem; 2009 Jan; 321(1-2):197-204. PubMed ID: 18985281 [TBL] [Abstract][Full Text] [Related]
59. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide. Grossman TR; Carrer M; Shen L; Johnson RB; Hettrick LA; Henry SP; Monia BP; McCaleb ML Mol Vis; 2017; 23():561-571. PubMed ID: 28855795 [TBL] [Abstract][Full Text] [Related]
60. Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Hagedorn PH; Yakimov V; Ottosen S; Kammler S; Nielsen NF; Høg AM; Hedtjärn M; Meldgaard M; Møller MR; Orum H; Koch T; Lindow M Nucleic Acid Ther; 2013 Oct; 23(5):302-10. PubMed ID: 23952551 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]